Shanghai Labway Clinical Laboratory Co., Ltd (SHE:301060)
China
· Delayed Price · Currency is CNY 9.12
-0.33 (-3.49%)
Jun 19, 2025, 2:45 PM CST
SHE:301060 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 1,656 | 1,742 | 1,668 | 4,182 | 1,766 | 1,231 | Upgrade
|
| Other Revenue | 0.25 | 0.25 | 6.72 | 17.5 | 11.91 | 6.83 | Upgrade
|
| Revenue | 1,657 | 1,742 | 1,674 | 4,199 | 1,778 | 1,238 | Upgrade
|
| Revenue Growth (YoY) | -2.45% | 4.05% | -60.13% | 136.14% | 43.62% | 7.34% | Upgrade
|
| Cost of Revenue | 1,350 | 1,410 | 1,345 | 2,420 | 1,105 | 842.97 | Upgrade
|
| Gross Profit | 306.93 | 332.53 | 329.31 | 1,779 | 672.9 | 395.22 | Upgrade
|
| Selling, General & Admin | 300.71 | 304.25 | 302.06 | 539.66 | 319.11 | 199.2 | Upgrade
|
| Research & Development | 61.48 | 59.97 | 48.86 | 109.4 | 39.44 | 21.8 | Upgrade
|
| Other Operating Expenses | 5.23 | 5.01 | 3.27 | 3.5 | 4.93 | 4.55 | Upgrade
|
| Operating Expenses | 372.26 | 394.89 | 484.87 | 708.33 | 378.75 | 237.04 | Upgrade
|
| Operating Income | -65.33 | -62.37 | -155.55 | 1,071 | 294.15 | 158.18 | Upgrade
|
| Interest Expense | -11.25 | -10.81 | -8.17 | -8.46 | -3.27 | - | Upgrade
|
| Interest & Investment Income | 11.85 | 10.63 | 5.58 | 3.53 | 8.93 | 8.15 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.02 | -1.02 | -0.57 | -0.56 | 0.02 | -0.24 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.09 | 1.52 | 0.99 | -0.05 | -0.21 | -5.39 | Upgrade
|
| EBT Excluding Unusual Items | -65.65 | -62.05 | -157.72 | 1,065 | 299.62 | 160.69 | Upgrade
|
| Impairment of Goodwill | - | - | -9.97 | -12.45 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -12.78 | -13.06 | -2.12 | 1.66 | 3.93 | 0.53 | Upgrade
|
| Gain (Loss) on Sale of Assets | 5.85 | 5.67 | 1.93 | -0.36 | -0.03 | 0.31 | Upgrade
|
| Asset Writedown | -23 | -17.15 | -1.26 | -115.07 | - | - | Upgrade
|
| Legal Settlements | -19.93 | -19.93 | -5.09 | - | - | - | Upgrade
|
| Other Unusual Items | 3.29 | 3.71 | 20.99 | -34.79 | 14.51 | 0.78 | Upgrade
|
| Pretax Income | -112.22 | -102.82 | -153.24 | 904.44 | 318.03 | 162.31 | Upgrade
|
| Income Tax Expense | -5.47 | -4.23 | 8.47 | 165.39 | 56.41 | 27.83 | Upgrade
|
| Earnings From Continuing Operations | -106.75 | -98.59 | -161.71 | 739.06 | 261.62 | 134.48 | Upgrade
|
| Minority Interest in Earnings | -11.84 | -10.85 | 20.12 | -121.73 | -57.78 | -24.1 | Upgrade
|
| Net Income | -118.59 | -109.44 | -141.59 | 617.32 | 203.84 | 110.38 | Upgrade
|
| Net Income to Common | -118.59 | -109.44 | -141.59 | 617.32 | 203.84 | 110.38 | Upgrade
|
| Net Income Growth | - | - | - | 202.85% | 84.68% | 19.66% | Upgrade
|
| Shares Outstanding (Basic) | 406 | 405 | 405 | 401 | 352 | 352 | Upgrade
|
| Shares Outstanding (Diluted) | 406 | 405 | 405 | 401 | 352 | 352 | Upgrade
|
| Shares Change (YoY) | 0.47% | 0.19% | 1.00% | 13.63% | 0.02% | -0.02% | Upgrade
|
| EPS (Basic) | -0.29 | -0.27 | -0.35 | 1.54 | 0.58 | 0.31 | Upgrade
|
| EPS (Diluted) | -0.29 | -0.27 | -0.35 | 1.54 | 0.58 | 0.31 | Upgrade
|
| EPS Growth | - | - | - | 166.52% | 84.64% | 19.68% | Upgrade
|
| Free Cash Flow | 185.87 | 139.7 | 148.1 | -145.91 | 104.63 | 123.33 | Upgrade
|
| Free Cash Flow Per Share | 0.46 | 0.34 | 0.37 | -0.36 | 0.30 | 0.35 | Upgrade
|
| Dividend Per Share | 0.200 | 0.200 | - | 0.300 | 0.300 | - | Upgrade
|
| Gross Margin | 18.53% | 19.09% | 19.67% | 42.37% | 37.84% | 31.92% | Upgrade
|
| Operating Margin | -3.94% | -3.58% | -9.29% | 25.50% | 16.54% | 12.78% | Upgrade
|
| Profit Margin | -7.16% | -6.28% | -8.46% | 14.70% | 11.46% | 8.91% | Upgrade
|
| Free Cash Flow Margin | 11.22% | 8.02% | 8.85% | -3.48% | 5.88% | 9.96% | Upgrade
|
| EBITDA | -3.08 | -2.73 | -106.34 | 1,133 | 338.96 | 201.87 | Upgrade
|
| EBITDA Margin | -0.19% | -0.16% | -6.35% | 26.98% | 19.06% | 16.30% | Upgrade
|
| D&A For EBITDA | 62.25 | 59.64 | 49.21 | 62.21 | 44.82 | 43.69 | Upgrade
|
| EBIT | -65.33 | -62.37 | -155.55 | 1,071 | 294.15 | 158.18 | Upgrade
|
| EBIT Margin | -3.94% | -3.58% | -9.29% | 25.50% | 16.54% | 12.78% | Upgrade
|
| Effective Tax Rate | - | - | - | 18.29% | 17.74% | 17.14% | Upgrade
|
| Revenue as Reported | 1,657 | 1,742 | 1,674 | 4,199 | 1,778 | 1,238 | Upgrade
|
| Advertising Expenses | - | 0.79 | 0.9 | 3.2 | 3.39 | 0.66 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.